RxDoctor Payments DataLook up a doctor →

Timothy Ballard

Acute Care · Knoxville, TNNPI 1053411355

Payments from drug & device makers

$46,671in general payments, 2019–2025

Across 806 payments — averaging $57.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$33K
  • Amgen$2K
  • Novartis$2K
  • Actelion Pharmaceuticals US, Inc.$832
  • AstraZeneca$762
  • Pfizer$642
  • plus $7K from 34 others

What the payments were for

  • Consulting fees$5001%
  • Speaking & faculty fees$26,75057%
  • Travel & lodging$3,1977%
  • Food & beverage$16,11035%
  • Education$1140%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,671 in reported general payments places this provider in the 95th percentile of 738 acute care providers in Tennessee.

See all acute care providers in Tennessee

Medicare billing

Part B allowed, 2024
$102,982
Medicare patients
575
Services billed
1,770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban292$284,798
XareltoRivaroxaban82$76,983
Repatha SureclickEvolocumab87$74,242
EntrestoSacubitril/Valsartan66$67,039
BrilintaTicagrelor70$41,375
JardianceEmpagliflozin44$39,877
FarxigaDapagliflozin Propanediol23$33,276
MultaqDronedarone Hcl12$10,824
Ranolazine ErRanolazine41$8,037
Prasugrel Hcl76$6,471
Atorvastatin Calcium245$2,256
Metoprolol Succinate165$1,958
Rosuvastatin Calcium129$1,706
Diltiazem 24hr Er (Cd)Diltiazem Hcl61$1,625
Nebivolol Hcl16$1,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$642$284,798292 claims
Johnson & JohnsonXarelto$610$76,98382 claims
AstraZenecaBrilinta, Farxiga$762$74,65193 claims
NovartisEntresto$1,734$67,03966 claims
Boehringer IngelheimJardiance$467$39,87744 claims
Sanofi-aventis U.S. LLCMultaq$66$10,82412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 738 acute care providers in Tennessee.

Other acute care in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →